EcoR1 Capital’s UroGen Pharma URGN Stock Holding History

EcoR1 Capital’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-402,300	Closed	-$20M	–	42
2018 Q1	$20M	Buy	+402,300	New	+$20.2M	2.01%	14

Other funds holding URGN

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

PAI

ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

MIH

Meitav Investment House Bene-Beraq, Israel $14.9B AUM 46.8% 1-Year Est. Return

HCM

Highline Capital Management New York $53.5M AUM 21.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

EcoR1 Capital's URGN Position: Q2 2018 in Review

EcoR1 Capital sold out of UroGen Pharma (URGN) in Q2 2018, closing a stake of 402,300 shares — an estimated $20M sold.

EcoR1 Capital first reported a position in URGN in Q1 2018 and held it in 1 quarter. The position peaked at $20M in Q1 2018. 60 funds tracked by Wall St. Rank hold URGN as of Q2 2018.

EcoR1 Capital reported no remaining UroGen Pharma position as of Q2 2018 after selling out during the quarter.
EcoR1 Capital sold 402,300 UroGen Pharma shares in Q2 2018, an estimated $20M.
EcoR1 Capital first reported a position in UroGen Pharma in Q1 2018 and held it in 1 quarter.
EcoR1 Capital's UroGen Pharma position peaked at $20M in Q1 2018.
60 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2018.

Based on EcoR1 Capital's 13F filing for Q2 2018, filed 14 Aug 2018.